Safety Information

Description Publish Date LINKS
Important safety information on Dolutegravir in Uganda
10/10/2018

Important safety information on Abacavir: Hypersensitivity reaction - educational slide deck 15/02/2024
Important safety information on SSRIs and SNRIs containing products in Uganda 03/02/2021
Important safety information on Ceruroxime sodium in Uganda (Safety Notification_Cefuroxime Class 4 Defect MHRA) 30/10/2023
Important safety information on Dolutegravir in Uganda (Safety Notification_Korean label update for Dolutegravir containing products) 01/11/2023
Important safety information on Cephalosporins in Uganda (Safety Notification_Cephalosporins and risk of seizure) 01/03/2023

Important safety information on Cephalosporins in Uganda (Safety Notification_Cephalosporins and risk of neurotoxicity)

07/03/2023

Important safety information on Amoxicillin / Amoxicillin and clavulanic acid containing products in Uganda

09/09/2023
Important safety information on Hepatitis B surface antigen recombinant vaccine in Uganda (Initial Safety Notification Engerix-B and Myelitis_November 2023) 17-11-2023
Important safety information on Hepatitis B surface antigen recombinant vaccine in Uganda (Updated Safety Notification Engerix-B and Myelitis_December 2023) 02-01-2024

Important safety information on Hepatitis B surface antigen recombinant vaccine (Updated Safety Notification Engerix-B and Myelitis_January 2024)

08/01/2024

Important safety information on Abacavir containing products - Regarding amendments to the instructions for medical use of medicines containing abacavir

19/03/2024

Important safety information on Hepatitis B surface antigen recombinant vaccine - Updated Safety Notification Engerix-B and Myelitis_May 2024

07/05/2024